Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
12:07pm, Monday, 16'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action.
Wall Street Analysts See a 77.28% Upside in Nektar (NKTR): Can the Stock Really Move This High?
10:56am, Monday, 16'th Mar 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
03:09am, Monday, 16'th Mar 2026
LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§1
New York, New York--(Newsfile Corp. - March 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therape
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
08:44am, Sunday, 15'th Mar 2026
NEW YORK, March 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ:
New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therape
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Nektar Therapeutics (NASDAQ:NKTR) Hits New 1-Year High Following Better-Than-Expected Earnings
01:13am, Saturday, 14'th Mar 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price reached a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The stock tr
New York, New York--(Newsfile Corp. - March 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therap
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASD
Law Offices of Howard G. Smith Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
02:36pm, Friday, 13'th Mar 2026
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Com
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
12:25pm, Friday, 13'th Mar 2026
NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 13'th Mar 2026
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar T
